Zarkali A, Thomas GEC, Zetterberg H & Weil RS. Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions. Nat. Communications. 2024 In press.
Dobreva I, Thomas J, Marr A, O’Connell R, Roche M, Hannaway N, Dore C, Rose S, Liu K, Bhome R, Baldwin-Jones S, Roberts J, Archibald N, Alston D, Amar K, Edwards E, Foley JA, Haunton VJ, Henderson EJ, Jha A, Magee C, Massey L, Ruiz-Mendoza E, Mohammed B, Patterson K, Ramaswamy B, Schrag AE, Silverdale M, Suarez-Gonzalez A, Subramanian I, Foltynie T, Williams-Gray CH, Yarnall AJ, Carroll C, Bale C, Hugill C & Weil RS. Improving conversations about Parkinson’s dementia. Movement Disorders Clinical Practice 2024 In press.
Bhome R, Verdi S, Martin SA, Hannaway N, Dobreva I, Oxtoby NP, Castro Leal G, Rutherford S, Marquand AF, Weil RS, Cole JH (Joint senior author). A neuroimaging measure to capture heterogeneous patterns of atrophy in Parkinson’s disease and dementia with Lewy bodies. NeuroImage Clinical. In press 2024.
Zarkali A, Hannaway N, McColgan P, Heslegrave AJ, Veleva E, Laban R, Zetterberg H, Lees AJ, Fox NC, Weil RS. Neuroimaging and plasma evidence of early white matter loss in Parkinson’s disease with poor outcomes. In press Brain Comms 2024.
Thomas GEC, Hannaway N, Zarkali A, Shmueli K, Weil RS. Longitudinal associations of magnetic susceptibility with clinical severity in Parkinson’s disease. Movement Disorders. Online ahead of print 2024.
Hannaway N, Zarkali A, Leyland LA, Bremner FD, Nicholas JM, Wagner SK, Roig M, Keane PA, Toosy AT, Chataway J Weil RS. Visual dysfunction is a better predictor than retinal thickness for dementia in Parkinson’s disease. JNNP 2023. 94(9):742-750
Bhome R, Thomas GEC, Zarkali A & Weil RS. Structural and Functional Imaging Correlates of Visual Hallucinations in Parkinson’s disease. Current Neurology & Neuroscience Reports. 2023. 112:105385
Thomas GEC, Zeidman P, Sultana T, Zarkali A, Razi A & Weil RS. Changes in both top-down and bottom-up effective connectivity drive visual hallucinations in Parkinson’s disease. Brain Communications. 2022. 5(1):fca329
Zarkali A, Luppi AI, Stamatakis EA, Reeves S, McColgan P, Leyland LA, Lees AJ, Weil RS. Changes in dynamic transitions between integrated and segregated states underlie visual hallucinations in Parkinson’s disease. Nature Communications Biology 2022. 5(1):928
Zarkali A & Weil RS. Using network approaches to unravel the mysteries of visual hallucinations in Lewy Body Dementia. Brain 2022. 145(6):1883-1885
Bhome R, Zarkali A, Thomas GEC, Iglesias JE, Cole JH & Weil RS. Thalamic white matter macrostructure and subnuclei volumes in Parkinson’s disease depression. Nat. Parkinson’s disease. 8(1)2. 2022
Oxtoby NP, Leyland LA, Aksman LM, Thomas GEC, Bunting EL, Wijeratne PA, Young AL, Zarkali A, Tan MXT, Bremner FD, Keane PA, Morris HR, Schrag AE, Alexander DC & Weil RS. Sequence of clinical and neurodegeneration events in Parkinson’s disease progression. Brain 2021. 144(3):975-988.
Longitudinal thalamic white and gray matter changes associated with visual hallucinations in Parkinson’s disease. Zarkali, A, McColgan P, Leyland, LA, Lees AJ & Weil RS. JNNP. 2021
How to understand it: Visual Hallucinations. Weil RS & Lees AJ. Practical Neurology. 2021.
Thomas EC, Zarkali A, Ryten M, Shmueli K, Gil Martinez AL, McColgan P, Leyland LA, Acosta-Cabronero J, Lees AJ & Weil RS. Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson’s disease. Brain 2021.
Zarkali A, McColgan P, Leyland LA, Lees AJ & Weil RS. Visual dysfunction predicts cognitive impairment and white matter degeneration in Parkinson’s disease. Movement Disorders 2021 in press
Zarkali A, McColgan P, Leyland LA, Lees AJ, Rees G & Weil RS. Organisational and neuromodulatory underpinnings of structural-functional connectivity decoupling in Parkinson’s disease. Nature Communications Biology 2020 in press.
Weil RS. Visual dysfunction and Parkinson’s disease. Movement Disorders 2020. 35(9):1499-1501
Zarkali A, McColgan P, Ryten M, Reynolds, Leyland LA, Lees AJ, Rees G & Weil RS. Dementia risk in Parkinson’s disease is associated with interhemispheric loss and determined by regional gene expression. Neuroimage Clinical 2020 in press.
Zarkali A, McColgan P, Ryten M, Reynolds, Leyland LA, Lees AJ, Rees G & Weil RS. Differences in network controllability and regional gene expression in Parkinson’s hallucinations. Brain 2020 in press.
Weil RS & Reeves S. Hallucinations in Parkinson’s disease: new insights into mechanisms and treatments. Advances in Clinical Neuroscience and Rehabilitation. 2020 in press.
Foley JA, Dore C, Zarkali A, Livington G, Cipolotti L, Mummery CJ & Weil RS. Evaluation of START (STrAtegies for RelaTives) adapted for carers of people with Lewy body dementia. Future Healthcare Journal 2020 in press
Zarkali A, McColgan P, Leyland LA, Lees AJ, Rees G, Weil RS, Fibre-specific white matter reductions in Parkinson’s hallucinations and visual dysfunction. Neurology. 2020
Thomas EC, Leyland LAL, Schrag AE, Lees AJ, Acosta Cabronero J, Weil RS. Brain iron deposition is linked with cognitive severity in Parkinson’s disease. JNNP 2020 in press
Weil RS, Hsu JK, Darby RR, Soussand L, Fox MD. Neuroimaging Parkinson’s disease dementia: Connecting the dots. Brain Comms 2019
Zarkali A, Adams RA, Stamatios P, Leyland LA, Rees G, Weil RS. Increased weighting on prior knowledge in Lewy Body-associated visual hallucinations. Brain Comms 2019
Leyland LA, Bremner FD, Mahmood R, Hewitt S, Durteste M, Cartlidge MRE, Lai MM, Miller LE, Saygin AP, Keane PA, Schrag AE and Weil RS. Visual tests predict dementia risk in Parkinson’s disease, Neurology Clinical Practice 2019
Weil RS, Winston JS, Leyland LA, et al. Neural correlates of early cognitive dysfunction in Parkinson’s disease. Annals of Clinical and Translational Neurology 2019
Lanskey JH, McColgan P, Schrag AE, Acosta-Cabronero J, Rees G, Morris HR, Weil RS. Can Neuroimaging predict dementia in Parkinson’s disease? Brain 2018
Weil RS, Kilner J, Haynes JD, Rees G. Neural correlates of perceptual filling-in of an artificial scotoma in humans. Proc Natl Acad Sci USA 2007; 104(12):5211-6
Weil RS, Watkins S and Rees G. Neural correlates of perceptual completion of an artificial scotoma in human visual cortex measured using functional MRI. Neuroimage. 2008;42(4):1519-28
Weil RS and Rees G. How does the brain fill-in the visual world? Advances in Clinical Neuroscience and Rehabilitation. 2009; 9(4):12-15
Weil RS, Plant GT, James-Galton M and Rees G. Neural correlates of hemianopic completion across the vertical meridian. Neuropsychologia. 2009;47(2):457-64
Weil RS, Furl N, Ruff CC, Symmonds M, Flandin G, Dolan RJ, Driver J, Rees G. Rewarding feedback after correct visual discriminations has general and specific influences on visual cortex. Journal of Neurophysiology. 2010; 104(3):1746-57
Song C, Kanai R, Fleming SM, Weil RS, Schwarzkopf DS, Rees G. Relating inter-individual differences in metacognitive performance on difference perceptual tasks. Consciousness and Cognition 2010; 20(4):1787-92
Weil RS and Rees G. Decoding the neural correlates of consciousness. Current Opinion in Neurology. 2010; 23(6):649-55
Weil RS, Fleming SM, Nagy Z, Dolan RJ, Rees G. Relating introspective accuracy to individual differences in brain structure. Science. 2010; 329(5998):1541-3
Weil RS and Rees G. A new taxonomy for perceptual filling-in. Brain Research Reviews. 2011; 67:40-55.
Weil RS, Wykes V, Carmel D, Rees G. Opposite effects of perceptual and working memory load on perceptual filling-in of an artificial scotoma. Cognitive Neuroscience. 2012;3(1):36-44
Weil LG, Fleming SM, Dumontheil I, Kilford EJ, Weil RS, Rees G, Dolan RJ, Blakemore SJ. The development of metacognitive ability in adolescence. Consciousness and Cognition. 2013; 22(1):264-71
Nageshwaran S, Mullin S, Cowley P, Dorward N, Mort D, Weil RS. Subarachnoid haemorrhage as presenting feature of lumbar spinal arteriovenous malformation. Practical Neurology. 2013; 13(5):319-21
Weil RS, McColgan P, Schrag AE et al. Reply: MRI findings of visual system alterations in Parkinson’s disease. Brain. 2017; 140(11):e70.
Weil RS, Costantini A, Schrag AE. Mild cognitive impairment in Parkinson’s disease – What is it? In press. Current Neurology and Neuroscience Reports. 2018.
Weil RS, Schrag A, Warren JD, Crutch SJ, Lees AJ, Morris HR. Visual dysfunction in Parkinson’s disease. Brain. 2016; 139(11):2827-2843.
Weil RS, Pappa K et al. The Cats-and-Dogs test: A tool to identify visuoperceptual deficits in Parkinson’s disease. Mov Disord. 2017
Weil RS, Lashley T, Bras J, Schrag AE, Schott JM. Current concepts and controversies in the pathogenesis of Parkinson’s disease dementia and dementia with Lewy bodies. F1000Res 2017;
Malek N, Weil RS, Bresner C et al. Features of GBA-associated Parkinson’s disease at presentation in the United Kingdom Tracking Parkinson’s study. In press. JNNP. 2018.
Weil RS, Schwarzopf DS et al. Assessing cognitive dysfunction in Parkinson’s disease: An online tool to detect visuo-perceptual deficits. Mov Disord. 2018.